mizagliflozin   Click here for help

GtoPdb Ligand ID: 9547

Synonyms: DSP-3235 | KWA 0711 | KWA-0711 | KWA0711
Compound class: Synthetic organic
Comment: Mizagliflozin is a novel orally bioavailable and selective sodium glucose co-transporter 1 (SGLT1) inhibitor. It acts locally in the intestinal lumen to block postprandial glucose absorption. It increases luminal water and is proposed to loosen stools [3,5].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 7
Rotatable bonds 14
Topological polar surface area 192.41
Molecular weight 564.32
XLogP 1.53
No. Lipinski's rules broken 2

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES OCC1OC(Oc2n[nH]c(c2Cc2ccc(cc2C)OCCCNCC(C(=O)N)(C)C)C(C)C)C(C(C1O)O)O
Isomeric SMILES OC[C@H]1O[C@@H](Oc2n[nH]c(c2Cc2ccc(cc2C)OCCCNCC(C(=O)N)(C)C)C(C)C)[C@@H]([C@H]([C@@H]1O)O)O
InChI InChI=1S/C28H44N4O8/c1-15(2)21-19(25(32-31-21)40-26-24(36)23(35)22(34)20(13-33)39-26)12-17-7-8-18(11-16(17)3)38-10-6-9-30-14-28(4,5)27(29)37/h7-8,11,15,20,22-24,26,30,33-36H,6,9-10,12-14H2,1-5H3,(H2,29,37)(H,31,32)/t20-,22-,23+,24-,26+/m1/s1
InChI Key LREHMKLEOJAVMQ-TXKDOCKMSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

No information available.
Summary of Clinical Use Click here for help
Mizagliflozin was progressed as a clinical candidate for potential to treat chronic constipation [1-2,4].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT05541939 Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects Phase 2 Interventional Vogenx, Inc.
NCT05721729 Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions Phase 2 Interventional Vogenx, Inc.
NCT02281630 Phase II Dose-Finding Study of KWA-0711 in Patients With Chronic Constipation (CC) Phase 2 Interventional Kissei Pharmaceutical Co., Ltd. 6